Baker & McKenzie's Australia Pharmaceuticals and Health Care lawyers work with market leaders including Pfizer, Schering-Plough, Hospira, Inc, Cardinal Health, CR Bard, Boston Scientific, Genetic Technologies, Victor Chang Cardiac Research, IBA Health, Sonic Healthcare and Bayer Australia to deliver a range of legal advice and representation.
Drawing on vast experience and industry experience, the group comprises lawyers with excellence in corporate and commercial, competition and consumer law, disputes (including product liability), employment, environment, intellectual property, regulatory, compliance and tax advice.
The Australia group is part of Baker & McKenzie's Global Pharmaceuticals & Health Care platform, which helps to facilitate sharing knowledge and skills to ensure that clients benefit from global experience.
Highlights of our experience includes, advising:
- A large health industry company of its arrangements with healthcare practitioners and other third-parties in at least 21 countries, including, conducting a global compliance and operational review;
- Hospira, Inc., on the AUD2.7 billion takeover of Mayne Pharma Limited by way of scheme of arrangement;
- Sonic Healthcare on the AUD400 million acquisition of Clinical Pathology Laboratories;
- IBA Health on the cross-border acquisition of iSoft Group plc and associated fundraising initiatives including an AUD165 million renounceable rights issue to shareholders, AUD300 million placement to institution investors, and debt raising;
- Bovigen, a US-based acquirer of gene marker technology and businesses, in a multi-jurisdictional transaction involving the negotiation of a series of complex licences with the CSIRO, various Cooperative Research Centres, industry organizations and universities, and reciprocal technology transfer, support services and research and development agreements. Pfizer subsequently acquired both Bovigen and Catapult Genetics, the other party to the transaction;
- Victor Chang Cardiac Research Institute on the commercialisation, management and protection of its intellectual property and on a range of agreements including research, material transfers, clinical trials, as well as testing and research on sample products at the pre-clinical trial stage;
- A global pharmaceutical company in proceedings brought in the Federal Court against our client and other companies arising out of the global vitamins cartel and also defending the subsequent civil class action.
Our lawyers hold key positions in industry associations and health committees, including AusBiotech and AmCham.
Our practices worldwide were highly recommended in the Life Sciences Industry and Regulatory Super League for 2008 featured in the PLC Cross-border Quarterly (April-June 2008): Life Sciences Review.